There is a need for greater level-1, translational-based evidence, especially randomized clinical trials, to better assess the efficacy of GLP-1R agonists as a pharmacological treatment choice for patients with IIM. This includes understanding the specific mechanisms of action by which GLP-1R agonists can ameliorate and manage symptoms of the various IIM subtypes. The gene discussed is GLP1R; the disease is acquired idiopathic inflammatory myopathy.